

CURRICULUM VITAE

Shuang Huang, Ph.D.

PRESENT ADDRESS: Department of Biochemistry and Molecular Biology
Medical College of Georgia
Georgia Regents University
Cancer Research Center Building, CN2177
1410 Laney Walker Blvd
Augusta, GA 30912

TELEPHONE: (706) 721-1637 (Office)
(858) 231-6259 (cell)

FAX: (706) 721-6608

E-MAIL: shuang@gru.edu

EDUCATION:

Ph.D. in Pharmacology, 1994
Baylor College of Medicine, Houston, Texas

B.Sc. in Neurobiology, 1983
Fudan University, Shanghai, China

PROFESSIONAL EXPERIENCE:

2012 – Professor with Tenure, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Regents University (formerly Georgia Health Sciences University), Augusta, GA

2009 – 2012 Associate Professor with Tenure, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA

2007 – 2009 Associate Professor, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA

2012 – Professor, Georgia Regents University Graduate School, Augusta, GA

2007 – 2012 Associate Professor, Georgia Health Sciences University Graduate School, Augusta, GA

2007 – Member, Molecular Oncology and Biomarker Program, Georgia Regents University Cancer Center, Augusta, GA

2000 – 2006 Assistant Professor, Department of Immunology, The Scripps Research Institute, La Jolla, CA

1997 – 2000 Senior Research Associate, Department of Immunology, The Scripps Research Institute, La Jolla, CA

1994 – 1997 Research Associate, Department of Immunology, The Scripps Research Institute, La Jolla, CA

1988 – 1994 Graduate Research Assistant, Department of Pharmacology, Baylor College of Medicine, Houston, TX

1983 – 1986 Research Assistant, Laboratory of Immunology, Shanghai College of Traditional Chinese Medicine, Shanghai, China

PEER-REVIEWED RESEARCH ARTICLES:

Ren S, Li X, Fan W, Chen J, Zhang X, Mu Y, Zhang H, Sun M, Liu C, **Huang S***, and Liu P*. (2014). MicroRNA-744/Transforming Growth Factor β 1 Functional Pair Regulates Liver Cirrhosis. Submitted to *J Hepatol*. (*co-corresponding authors)

Dong G, **Huang S**, Ding H-F, and Dong Z. (2014). mTOR contributes to ER stress and associated apoptosis in renal tubular cells. *Am J Physiol Renal Physiol*, in press.

Teoh J-P, Park K-M, Wang Y, Hu Q, Kim S, Wu G, **Huang S**, Maihle N, and Kim I-M. (2014). Endothelin-1/Endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. Submitted to *Mol Pharmacol*.

Zha Y, Xia Y, Ding J, Choi J-H, Yang L, Dong Z, Yan C, and **Huang S**, and Ding H-F. (2014) ;. *Cell Death Dis*, in press.

Hong S, Noh H, Teng Y, Shao J, Rehmani H, Ding H-F, Dong Z, Su S-B, Shi H, Kim J, and **Huang S**. (2014). SHOX2 is a direct microRNA-375 target and a novel epithelial-mesenchymal transition inducer in breast cancer cells. *Neoplasia*, 16:279-290. (cover article) (PMID: 24746361)

Li Y, Chao F, Huang B, Liu D, Kim J, and **Huang S**. (2014). HOXC8 promotes breast tumorigenesis by transcriptionally facilitating cadherin-11 expression. *Oncotarget*, 6: 2596-2607. (PMID: 24810778)

Tian FJ, An LN, Wang GK, Zhu JQ, Li Q, Zhang YY, Zeng A, Zou J, Zhu RF, Han XS, Shen N, Yang HT, Zhao XX, **Huang S**, Qin YW, and Jing Q. (2014). Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. *Cardiovasc Res*, 103:100-110.

Ding J, Li T, Wang X, Zhao E, Choi J-H, Yang L, Zha Y, Dong Z, **Huang S**, Asara JM, Cui H, and Ding H-F. (2013). The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. *Cell Metab*, 18:896-907.

Wang X, Choi JH, Ding J, Yang L, Ngoka L, Lee E, Zha Y, Mao L, Jin B, Ren M, Cowell J, **Huang S**, Shi H, Cui H, and Ding H-F. (2013). HOXC9 directly regulates distinct sets of genes to coordinate diverse cellular processes during neuronal differentiation. *BMC Genomics*, 14:830.

Peng M, Zhang H, Jaafar L, Risinger JI, **Huang S**, Mivechi NF, and Ko L. (2013). Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations. *J Biol Chem*, 288:33387-97.

1. Shao J, Teng T, Padia R, Hong S, Noh H, Xie X, Mumm JS, Dong Z, Ding H-F, Cowell J, Kim J, Han J, and **Huang S**. (2013). COP1 and GSK3 β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. *Neoplasia*, 15:1075-85. (PMID:24027432)

2. Zhang H, Guan Y, Lu YY, Hu YY, **Huang S**, Su SB. (2013). Circulating miR-583 and miR-663 refer to ZHENG differentiation in chronic hepatitis B. *Evid Based Complement Alternat Med*, 2013:751341.
3. Wu J, Jiang H, Zhang M, Zhang Y, Luo S, Sun F, **Huang S**, Li H. (2013). Caspase-mediated cleavage of C53/LZAP protein causes abnormal microtubule bundling and rupture of the nuclear envelope. *Cell Res*, 23:691-704.
4. Hu Q, Lu YY, Noh H, Hong S, Dong Z, Ding H-F, Su SB, and **Huang S**. (2013). Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. *Oncogene*, 32: 3933-3943. (PMID: 22986534)
5. Hong S, Noh H, Chen H, Padia R, Pan ZK, Su S, Jing Q, Ding H-F, and **Huang S**. (2013). Signaling by p38 MAPK stimulates nuclear localization of the microprocessor component p68 for processing of selected primary microRNAs. *Sci Signal*, 6:ra16. (PMID: 23482664)
6. Luo D, Wilson JM, Harvel N, Liu J, Pei L, **Huang S**, Hawthorn L, and Shi H. (2013). A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. *J Translational Medicine*, 11:57.
7. Patil M, Pabla N, **Huang S**, and Dong Z. (2013). Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization. *Cell Cycle*, 12:1-5.
8. Zhang H, Li QY, Guo ZZ, Guan Y, Du J, Lu YY, Hu YY, Liu P, **Huang S**, and Su SB. (2012). Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. *World J Gastroenterol*, 18:5188-5196.
9. Zha Y, Ding E, Yang L, Mao L, McCarthy B, **Huang S**, and Ding H-F (2012). Functional dissection of HOXD cluster genes in regulation of neuroblastoma cell proliferation and differentiation. *PLoS One*, 7:e40728.
10. Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, **Huang S**, Cui H, Ding H-F. (2012). Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. *Oncogene*, 31:3785-3795.
11. Wan Q, Liu J, Zheng Z, Zhu H, Chu X, Dong Z, **Huang S**, and Du Q. (2012). Entosis without matrix detachment – regulation of initial cell-cell contact formation by Par3-Lgl antagonism. *Mol Biol Cell*, 23:2076-2091.
12. Periyasamy-Thandavan S, Takhar S, Singer A, Dohn MR, Jackson WH, Welborn AE, LeRoith D, Marrero M, Thangaraju M, **Huang S**, and Schoenlein PV. (2012). Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. *Breast Cancer Res*, 14:R52.
13. Qi MY, Wang ZZ, Zhang Z, Shao Q, Zeng A, Li XQ, Li WQ, Wang C, Tian FJ, Li Q, Zou J, Qin YW, Brewer G, **Huang S**, and Jing Q. (2012) AU-rich element-dependent

- translation repression requires the cooperation of tristetraprolin and RCK/P54. *Mol Cell Biol*, 32:913-928.
14. Li Y, Guo Z, Chen H, Dong Z, Pan ZK, Ding HF, Su SB, and **Huang S**. (2011). HOXC8-dependent cadherin 11 expression facilitates breast cancer cell migration through Trio and Rac. *Genes Cancer*, 2:880-888. (PMID: 22593800)
 15. Pabla N, Dong G, Jiang M, **Huang S**, Kumar V, Messing R, and Dong Z. (2011). Inhibition of PKC δ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. *J Clin Invest*, 121:2709–2722.
 16. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY, **Huang S**, and Su SB. (2011). Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. *Eur J Cancer*, 47:2240-2247.
 17. Wei Q, Hill WD, Su Y, **Huang S**, and Dong Z. (2011). Heme oxygenase-1 induction contributes to renoprotection by G-CSF during rhabdomyolysis-associated acute kidney injury. *Am J Physiol Renal Physiol*, 301:F162-170.
 18. Noh H, Hong S, Dong Z, Pan ZK, Jing Q, and **Huang S**. (2011). Impaired microRNA processing increases breast cancer cell invasion by upregulating urokinase plasminogen activator expression. *Genes Cancer*, 2:140-150. (PMID: 21779487)
 19. Zhang Z, Zou J, Wang GK, Zhang JT, **Huang S**, Qin YW, and Jing Q. (2011). Uracils at nucleotide position 9-11 are required for the rapid turnover of miR-29 family. *Nucleic Acids Res*, 39:4387-4395.
 20. Pan ZK, Fisher C, Li JD, Jiang Y, **Huang S**, and Chen LY. (2011). Bacterial LPS up-regulated TLR3 expression is critical for antiviral response in human monocytes: evidence for negative regulation by CYLD. *Int Immunol*, 23:357-364.
 21. Doerner AM, Chen LY, Ye RD, Yong J, **Huang S**, and Pan ZK. (2011). Cell type-specific release of matrix-metallo-proteinase-9 by bacterial chemoattractant in human blood phagocytic leukocytes. *Int J Clin Exp Med*, 4:67-73.
 22. Chen H, Wu XF, Pan ZK, and **Huang S**. (2010). Integrity of SOS1/EPS8/AB11 determines ovarian cancer metastasis. *Cancer Res*, 70:9979-9990. (PMID: 21118970)
 23. Pan WW, Li JD, **Huang S**, Papadimos TJ, Pan ZK, and Chen LY. (2010). Synergistic activation of nuclear factor κ B (NF- κ B) by bacterial chemoattractant and tumor necrosis factor α (TNF α) is mediated by p38MAPK-dependent RelA acetylation. *J Biol Chem*, 285:34348-54.
 24. Li Y, Zhang M, Chen H, Dong Z, Ganapathy V, Thangaraju M, and **Huang S**. (2010). Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. *Cancer Res*, 70:7894-7904. (PMID: 20736365)
 25. Bhatt K, Zhou L, Mi QS, **Huang S**, She JX, and Dong Z. (2010). MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. *Mol Medicine*, 16: 409-416.
 26. Cho SG, Du Q, **Huang S**, and Dong Z. (2010). Drp1 dephosphorylation in ATP-

- depletion-induced mitochondrial injury and tubular cell apoptosis. *Am J Physiol Renal Physiol*, 299: F199-206.
27. Kwon IK, Wang R, Thangaraju M, **Huang S**, Liu K, Dashwood R, Dulin N, Ganapathy V, and Browning DD. (2010) PKG inhibits TCF signaling in colon cancer cells by blocking β -catenin expression and activating FOXO4. *Oncogene*, 29: 3423-3434.
 28. Chen HM, Zhu G, Li Y, Padia RN, Dong Z, Pan ZK, Liu K, and **Huang S**. (2009). Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. *Cancer Res*, 69: 9228-9235. (PMID: 19920183)
 29. Mukherjee S, Chen LY, Papadimos TJ, **Huang S**, Zuraw BL, and Pan ZK. (2009). LPS-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. *J Biol Chem*, 284: 29391-29398.
 30. Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN, Pan ZK, Dong Z, and **Huang S**. (2009). Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. *Oncogene*, 28: 3047-3057. (PMID: 19543320)
 31. Huang X, Chen LY, Doerner AM, Pan WW, Smith L, **Huang S**, Papadimos TJ, Pan ZK. (2009). An atypical protein kinase C (PKC ζ) plays a critical role in lipopolysaccharide-activated NF- κ B in human peripheral blood monocytes and macrophages. *J Immunol*, 182: 5810-5815.
 32. Jiang M, Wang CY, **Huang S**, Yang T, and Dong Z. (2009). Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. *Am J Physiol Renal Physiol*, 296: F983-F993.
 33. Chen LY, Pan WW, Chen M, Li JD, Liu W, Chen G, **Huang S**, Papadimos TJ Pan ZK. (2009). Synergistic induction of inflammation by bacterial products lipopolysaccharide and fMLP: an important microbial pathogenic mechanism. *J Immunol*, 182:2518-2524.
 34. McGough JM, Yang D, **Huang S**, Georgi D, Hewitt SM, Tanzer M, Rocken C, Tanzer M, Ebert MPA, and Liu K. (2008). DNA methylation represses IFN- γ -induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. *Mol Cancer Res*, 6:1841-1851.
 35. Chen H, Liang C, Zhang L, **Huang S**, and Wu X. (2008). Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 and IIB) cervical cancer: a randomized study. *Gynecol Oncol*, 110:308-315.
 36. Pabla N, **Huang S**, Mi QS, Daniel R, and Dong Z. (2008). ATR-Chk2 signaling in p53 activation and DNA damage cisplatin-induced apoptosis. *J Biol Chem*, 283:6572-6583.
 37. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, and **Huang S**. (2008). Protein kinase C α -CARMA3 signaling axis links Ras to NF- κ B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. *Oncogene*, 27: 1273-1280. (PMID: 17724468)
 38. Mahanivong C, Yu J, and **Huang S**. (2007). Elevated urokinase-specific surface receptor expression is maintained through its Interaction with urokinase plasminogen activator.

- Mol Carcinogenesis*, 46: 165-175. (PMID: 17186542)
39. Mahanivong C, Krueger J, Bian D, Reisfeld RA, and **Huang S**. (2006). A simplified cloning strategy for the generation of an endothelial cell selective recombinant adenovirus vector. *J Virol Methods*, 135:127-135. (PMID: 16581140)
 40. Bian D, Mahanivong C, Yu J, Frisch SM, Pan ZK, Ye RD, and **Huang S**. (2006). The G_{12/13}-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. *Oncogene*, 25: 2234-2244. (PMID: 16301993)
 41. Xu Y, **Huang S**, Liu ZG, and Han J. (2006). Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. *J Biol Chem*, 281: 8788-8795.
 42. Pan Q, Kravchenko V, Katz A, **Huang S**, Li M, Mathison JC, Kobayashi K, Flavell RA, Schreiber RD, Goeddel D, Ulevitch RJ. (2006). NF- κ B-inducing kinase regulates selected gene expression in the Nod2 signaling Pathway. *Infect Immun*, 74: 2121-2127.
 43. Chen LY, Doerner A, Lehmann PF, **Huang S**, Zhong G, and Pan ZK. (2005). A novel protein kinase C (PKC ϵ) is required for fMet-Leu-Phe induced activation of NF- κ B in human peripheral blood monocytes. *J Biol Chem*, 280: 22497-22501.
 44. Li H, Ye X, Mahanivong C, Bian D, Chun J, and **Huang S**. (2005). Signaling mechanisms responsible for lysophosphatidic acid- induced urokinase plasminogen activator expression in ovarian cancer cells. *J Biol Chem*, 280: 10564-10571. (PMID: 15653692)
 45. Jing Q, **Huang S**, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram, H, and Han J. (2005). Involvement of microRNA in AU-rich element mediated mRNA stability. *Cell*, 120: 623-634.
 46. Yu J, Bian D, Mahanivong C, Chang RK, Zhou W, and **Huang S**. (2004). p38 mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. *J Biol Chem*, 279: 50446-50454. (PMID: 15371454)
 47. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, and **Huang S**. (2004). Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. *Cancer Res*, 64: 4209-4217. (PMID: 15205333)
 48. Chen LY, Zuraw BL, Zhao M, Liu FT, **Huang S** and Pan ZK. (2003). Involvement of protein tyrosine kinase in Toll-like receptor 4-mediated NF- κ B activation in human peripheral blood monocytes. *Am J Physiol Lung Cell Mol Physiol*, 284: L607-L613.
 49. Hsia DA, Mitra SK, Hauck CR, Streblov DN, Nelson JA, Ilic D, **Huang S**, Li E, Nemerow GR, Leng J, Spencer KSR, Cheresh DA, and Schlaepfer DD. (2003). Differential regulation of cell motility and invasion by FAK. *J Cell Biol*, 160: 753-767.
 50. Ge B, Xiong X, Jing Q, Mosley JL, Filose A, Bian D, **Huang S**, and Han J. (2003). TAB1 β (transforming growth factor- β -activated protein kinase 1-binding protein 1 β), a novel splicing variant of TAB1 that interacts with p38 α but not TAK1. *J Biol Chem*, 278: 2286-2293.
 51. Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK, Han J, and **Huang S**.

- (2002). Rac1-MKK3-p38-MAPKAPK2 signaling pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. *J Biol Chem*, 277: 48379-48385. (PMID: 12377770)
52. Chen LY, Zuraw B, Liu FT, **Huang S**, and Pan ZK (2002). IL-1 receptor-associated kinase and low molecular weight GTPase RhoA signal molecules are required for bacterial lipopolysaccharide-induced cytokine gene transcription. *J Immunol*, 169: 3934-3939.
 53. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, **Huang S**, and Sun P. (2002). Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic *ras*-induced premature senescence. *Mol Cell Biol*, 22:3389-3403.
 54. Chen J, Baskerville C, Han Q, Pan ZK, and **Huang S**. (2001). α_v integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. *J Biol Chem*, 276: 47901-47905. (PMID: 11606583)
 55. **Huang S**, Chen LY, Zuraw BL, Ye RD, and Pan ZK. (2001). Chemoattractant-stimulated NF- κ B activation is dependent on the low molecular weight GTPase RhoA. *J Biol Chem*, 276:40977-40981.
 56. Wu E, Fernandez J, Fleck SK, Von Seggern DJ, **Huang S**, and Nemerow GR. (2001). A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37. *Virology*, 279: 78-89.
 57. Li, R.C., Ping, P., Zhang, J., Wead, W.B., Cao, X., Gao, J., Zheng, Y., **Huang, S.**, Han, J. and Bolli, R. (2000). PKCepsilon modulates NF-kappaB and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes. *Am J Physiol Heart Circ Physiol*, 279: H1679-1689.
 58. **Huang, S***, New, L., Pan, Z., Han, J. and Nemerow, G.R. (2000). Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38 α mitogen-activated protein kinase activity. *J Biol Chem*, 275: 12266-12272. *corresponding author
 59. **Huang S**, Stupack D, Liu A, Cheresch DA, and Nemerow GR. (2000). Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of α_v integrins. *Oncogene*, 19: 1915-1923.
 60. Von Seggern DJ, **Huang S**, Fleck SK, Stevenson SC, and Nemerow GR. (2000). Adenoviral vector pseudotyping in fiber-expressing cell lines: improved transduction of EBV-transformed B cells. *J Virol*, 74: 354-362.
 61. Ping P, Zhang J, **Huang S**, Cao X, Tang XL, Li RCX, Zheng YT, Qiu Y, Clerk A, Sugden P, Han J, and Bolli R. (1999). PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits. *Am J Physiol Heart Circ Physiol*, 277: H1771-H1785.
 62. **Huang S**, Reddy V, Dasgupta N, and Nemerow GR. (1999). A single amino acid in the adenovirus type 37 fiber confers binding to human conjunctival cells. *J Virol*, 73: 2798-2802.

63. Chen W, **Huang S**, and Cooper NR. (1998). Levels of p53 in EBV infected cells determine cell fate: apoptosis, cell cycle arrest at the G1/S boundary without apoptosis, cell cycle arrest at G2/M boundary without apoptosis, or unrestricted proliferation. *Virology*, 251:217-226.
64. Kato Y, Tapping RI, **Huang S**, Watson MH, Ulevitch RJ, and Lee JD. (1998). Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. *Nature*, 395: 713-716.
65. Nemoto S, Xiang J, **Huang S**, and Lin A. (1998). Induction of apoptosis by SB202190 through inhibition of p38 β mitogen-activated protein kinase. *J Biol Chem*, 273:16415-16420.
66. Wang K, **Huang S**, Kapoor-Munshi A, and Nemerow GR. (1998). Adenovirus internalization and infection requires dynamin. *J Virol*, 72: 3455-3458.
67. Wang Y, **Huang S**, Sah VP, Ross J, Brown JH, Han J, and Chien KR. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of p38 mitogen-activated protein kinase family. *J Biol Chem*, 273:2161-2168.
68. **Huang S**, StupackD, Mathis P, Wang Y, and Nemerow GR. (1997). Growth arrest of Epstein-Barr virus immortalized B-lymphocytes by adenovirus delivered ribozymes. *Proc Natl Acad Sci USA*, 94:8156-8161.
69. **Huang S**, Jiang Y, Li Z, Nishida E, Mathias P, Lin S, Ulevitch RJ, Nemerow GR, and Han J. (1997). Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. *Immunity*, 6:739-749.
70. Rajagopal S, **Huang S**, Albitar M, and Chakrabarty S. (1997). Control of fibronectin receptor expression by fibronectin: antisense fibronectin RNA downmodulates the induction of fibronectin receptor by transforming growth factor. *J Cell Physiol*, 170:138-144.
71. Steward P, Chiu C, **Huang S**, Muir T, Zhao Y, Chait B, Mathias P, and Nemerow GR. (1997). Cryo-EM visualization of exposed RGD epitope on adenovirus that escapes antibody neutralization. *EMBO J*, 16:1189-1198.
72. Manshour T, **Huang S**, Sundaresan A, Chakravarty M, Chakrabarty S, and Albitar M. (1997). Development of a partial fibronectin knockout transgenic mouse model. *Transgenics*, 2:167-174.
73. Chakrabarty S, and **Huang S**. (1996). Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase C expression. *J Exp Therapeutics & Oncol*, 1:218-221.
74. **Huang S**, Kamata T, Takada Y, Ruggeri ZM, and Nemerow GR. (1996). Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cell. *J Virol*, 70:4502-4508.
75. **Huang S**, Endo RI, and Nemerow GR. (1995) Upregulation of integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ on human monocytes facilitates adenovirus-mediated gene delivery. *J Virol*, 69:2257-2263.

76. Rajagopal S, **Huang S**, Moskal TL, Lee BN, El-naggar A, and Chakrabarty S. (1995). Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells. *Int J Cancer*, 62:661-667.
77. Moskal TL, **Huang S**, Ellis LM, Fritsche HA, and Chakrabarty S. (1995). Serum levels of transforming growth factor α in gastrointestinal cancer patients. *Cancer Epidemiol Biomarkers & Prevention*, 4:127-131.
78. Chakrabarty S, Rajagopal S, and **Huang S**. (1995). Expression of antisense epidermal growth factor RNA downmodulates the malignant behavior of human colon cancer cells. *Clin Exp Metastasis*, 13:191-195.
79. Chakrabarty S, and **Huang S**. (1995). Role of protein kinase C α in the induction of carcinoembryonic antigen by transforming growth factor β . *J Cell Physiol*, 164:148-153.
80. **Huang S**, Varani J, and Chakrabarty S. (1994). Control of AKR fibroblast phenotype by fibronectin: regulation of cell-surface fibronectin binding receptor by fibronectin. *J Cell Physiol*, 161:470-482.
81. **Huang S**, and Chakrabarty S. (1994). Expression of antisense fibronectin RNA in human colon carcinoma cells disrupts the regulation of carcinoembryonic antigen by transforming growth factor. *J Biol Chem*, 269:28764-28768.
82. Chakrabarty S, **Huang S**, Moskal TL, and Fritsche HA. (1994). Elevated serum levels of transforming growth factor- α in breast cancer patients. *Cancer Lett*, 79:157-160.
83. **Huang S**, and Chakrabarty S. (1994). Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factor- β . *Int J Cancer*, 57:742-746.
84. **Huang S**, Trujillo JM, and Chakrabarty S. (1992). Proliferation of human colon cancer cells: role of epidermal growth factors. *Int J Cancer*, 52:978-986.
85. **Huang S**, Lin PF, Fan D, Price JE, Trujillo JM, and Chakrabarty S. (1991). Growth modulation by epidermal growth factor (EGF) in human colonic carcinoma cells: constitutive expression of the human EGF gene. *J Cell Physiol*, 148:220-227.

REVIEW ARTICLES:

1. Li Y and **Huang S**. (2012). Cadherins in epithelial-mesenchymal transition.
2. Hao Z, and Huang S. (2014). E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Submitted to *Front BioSci*.
3. Zheng N, Dai JY, Cao H, Sun S, Fang J, Li Q, Su SB, Zhang YY, Qiu M, **Huang S**. (2013). Current understanding on anti-hepatocarcinoma effects of Xiao Chai Hu Tang and its constituents. *Evid Based Complement Alternat Med.*, 2013:529458. (PMID: 23853661)
4. Noh H, Hong S, and **Huang S**. (2013). Role of urokinase receptor in tumor progression and development. *Theranostics*, 3:487-95. (PMID: 23843896)

5. Wang Y, and **Huang S.** (2000). Adenovirus technology for gene manipulation and function Studies. *Drug Discovery Today*, 5:10-16.
6. Gallick GE, Garcia RA, Stanley CA, Moskal TL, **Huang S,** and Chakrabarty S. (1994). Molecular alterations during colon tumorigenesis: an overview of growth regulatory pathways and potential therapeutic implications. *Cancer Bulletin*, 46:296-302.

INVITED PRESENTATION:

Post-2000

1. Georgia Regents University Confucius Institute, Augusta, GA. March 28, 2014.
2. Second Military Medical University Changhai Hospital, Shanghai, China. July 10, 2013.
3. Second Military Medical University Changhai Hospital, Shanghai, China. December 6, 2012.
4. University of Texas Health Science Center at San Antonio, Department of Cell Biology, February 14, 2012.
5. Shanghai Pulmonary Hospital, Center of Translation Medicine, Shanghai, China. November 18, 2011.
6. Zhejiang University College of Life Science, Hangzhou, Zhejiang, China. November 15, 2011.
7. Zhejiang University Institute of Life Science, Hangzhou, Zhejiang, China. November 14, 2011
8. Shanghai University of Traditional Chinese Medicine, Shanghai, China. November 10, 2011.
9. Albany State University Department of Biology, Albany, GA. October 18, 2011
10. Nankai University School of Medicine, Tianjin, China. July 4, 2011.
11. Medical College of Georgia Institute of Molecular Medicine and Genetics, January 14, 2010.
12. Medical College of Georgia Cancer Center RIP meeting, Augusta, Georgia. December 2, 2009.
13. University of Georgia School of Veterinary Medicine, Department of Physiology & Pharmacology, Athens, GA. March 23, 2009.
14. University of Southern California School of Pharmacy, Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, Los Angeles, CA. October 1, 2008.
15. Emory University, Winship Cancer Institute, Atlanta, GA. June 13, 2008.
16. Medical College of Georgia Cancer Center RIP meeting, Augusta, Georgia. January 7, 2008.
17. Fudan University, School of Life Science, Shanghai, China. October 25, 2007.

18. Peking University, School of life Science, Beijing, China. October 12, 2007.
19. Medical College of Georgia Cancer Center RIP meeting, Augusta, Georgia. May 5, 2007.
20. Wayne State University School of Medicine, Department of Pathology, Detroit, MI. January 10, 2007.
21. Shanghai University of Traditional Chinese Medicine, Shanghai, China. July 5, 2006.
22. Medical University of Ohio, Department of Biochemistry & Cancer Biology, Toledo, OH. April 17, 2006.
23. Medical College of Ohio, Department of Medical Microbiology & Immunology, Toledo, OH. April 27, 2005

Pre-2000

1. American Red Cross Holland Laboratory, Department of Biochemistry, Rockland, MA. January, 5, 1999.
2. Creighton University, Department of Microbiology and Immunology, Omaha, NE. February, 4, 1999.
3. University of Delaware, Department of Biological Science, Newark, DE. March 20, 1999.
4. University of Pennsylvania, School of Veterinary Medicine, Department of Pathobiology, Pennsylvania, PA. April 10, 1999.

POSTDOCTORAL FELLOWSHIP:

1/1996 – 12/1997 American Cancer Society.

HONORS AND AWARDS:

1993 Chosen as platform speaker for annual graduate student symposium, Baylor College of Medicine.

2006 – 2010 Visiting Professorship, Shanghai University of Traditional Chinese Medicine, Shanghai, China

2011 – 2014 Eastern Scholar Lecture Professorship (Adjunct), Shanghai University of Traditional Chinese Medicine, Shanghai, China

2012 – 2015 Professorship (Adjunct), Shanghai University System Traditional Chinese Medicine Internal Medicine E-Institute

GRANT SUPPORT:

Ongoing:

Role of SHOX2 in breast tumor progression and metastasis
 R01, National Cancer Institute (CA187152)
 August 1, 2014 to July 31, 2019

Potential of Targeting PDE1C/2A for Suppressing Metastatic Ovarian Cancers
Pilot Award, Department of Defense Ovarian Cancer Research Program
July 1, 2013 to June 30, 2015

Pending:

1. Control of microRNA biogenesis by PKC- η /ILF3 in breast cancer cells
R21, National Cancer Institute (CA187831)
Received impact score of 30 with percentile of 18; will be resubmitted to in October 2014
2. Unique role of LPAR3 in ovary tumorigenesis
R01, National Cancer Institute (CA193614)
Submitted on June 5, 2014; will be reviewed in October, 2014

Completed:

1. Vitronectin and integrin $\alpha\beta 3$ in human ovarian carcinomas.
Idea Award, Department of Defense Ovarian Cancer Research Program
July 1, 2000 to June 30, 2003
2. Adenovirus-mediated gene therapy in human ovarian cancers.
New Investigator Award, California Cancer Research Program
July 1, 2000 to June 30, 2003
3. Endothelial cell-targeted adenoviral vector for suppressing breast malignancies.
Idea Award, Department of Defense Breast Cancer research Program
April 1, 2002 to March 31, 2005
4. Identify diagnosis biomarkers of prostate cancer.
Idea Development Award, Department of Defense Prostate Cancer Research Program
July 1, 2003 to June 30, 2006
5. The regulation of uPA and uPAR in human carcinoma cells.
R01, National Cancer Institute (CA093926)
July 1, 2002 to May 31, 2012
6. Combating lung cancer metastasis by raising intracellular cAMP concentration.
Concept Award, Department of Defense Lung Cancer Research Program
August 1, 2012 to July 31, 2013
7. MAPK-activated kinase 2-stimulated endothelial cell migration.
R01, National Heart, Lung and Blood Institute (HL083335)
June 1, 2008 to May 31, 2014

SCIENTIFIC AND PROFESSIONAL SOCIETIES:

2000-present American Association of Cancer Research
2000-present American Society of Biochemistry and Molecular Biology

OTHER PROFESSIONAL EXPERIENCE:

Grant Review

Mail Reviewer, NIH Tumor Microenvironment (TME) Study Section; 2005
Panel Reviewer, Department of Defense Ovarian Cancer Research Program; 2006 – 2010, 2012, 2013
Temporary Member, NIH Tumor Microenvironment (TME) Study Section; 2006, 2007, 2009
Mail Reviewer, Florida Department of Health Bankhead-Colely Cancer Research Program; 2010, 2011
Mail Reviewer, Israel Science Foundation; 2011, 2012.
Reviewer, NIH Special Emphasis Panel/Scientific Review Group ZRG1 F09-P (Oncological Science Fellowship); 2012 – 2014
Reviewer, NIH NCI Omnibus; 2013
Member of Intramural Grants Program Review Committee, Georgia Regents University; 2012 – present

Journal Review

Senior Editorial Board Member, *American Journal of Translational Research*; 2010-present
Editorial Board Member, *Journal of Integrative Medicine*; 2014-2018

Ad hoc Reviewer for the following journals:

J Biol Chem, Oncogene, Blood, Proc Natl Aca Sci USA, Mol Biol Cell, Mol Cell Biochemistry, Mol Cancer, BBA, TIBS, BMC Cell Biol, Int J Cancer, Future Medicine, Protein&Cell, Cancer Lett, J Mol Histol, Br J Cancer, Fertil Steril, J Cell Physiol, Cancer Biol Ther, PLoS One, J Invest Dermatol, Gene, Evid Based Complement Alternat Med, BBA-Molecular Basis of Disease, Mol Cell Biol, Current Cancer Drug Targets

UNIVERSITY SERVICES:

Member of Biochemistry and Cancer Biology Ph.D. Committee, Georgia Regents University; 2012 – present
Chair of Department of Biochemistry and Molecular Biology Promotion and Tenure Committee, Medical College of Georgia; 2014
Member of Department of Biochemistry and Molecular Biology Promotion and Tenure Committee, Medical College of Georgia; 2010, 2012, 2013
Member of Department of Biochemistry and Molecular Biology Chair Search Committee, Medical College of Georgia, Georgia Regents University; 2014
Chair of Department of Biochemistry and Molecular Biology Faculty Search Committee, Medical College of Georgia, Georgia Health Sciences University; 2011 – 2013
Member of Department of Biochemistry and Molecular Biology Faculty Search Committee, Medical College of Georgia; 2008 – 2010
Dean's Representative (Georgia Health Sciences University College of Graduate Studies); 2008 - 2010
Member of Academic Standards Committee (ASC), Georgia Regents University Graduate School; 2009 – present

TEACHING ACTIVITIES:

Course Director:

Georgia Regents University Graduate School:

COGS 8021 Biochemistry & Gene Regulations (2013 – present)

Courses Taught:

Georgia Regents University Graduate School:

COGS 8021 Biochemistry & Gene Regulations (2012 – present)

BMB 8021 Current Topics & Techniques in Biochemistry and Molecular Biology (2007-present)

SGS 8210 Fundamentals of Oncology (2008 – present)

Georgia Regents University Medical College of Georgia Teaching:

MEDI 5135 Biochemistry (2008 – 2011, 2014)

Dissertation Committees:

1. Huijun Chen, Doctorate Graduate Student, Medical College of Georgia/Wuhan University Joining Program – Primary Advisor (2007 – 2010)
2. Hyongsoon Noh, Doctoral Graduate Student, Georgia Regents University Graduate School – Primary Advisor (2008 – 2013)
3. Hina Rehmani, Doctoral Graduate Student, Georgia Regents University College of Graduate Studies – Primary Advisor (2013 – present)
4. Kirti Bhatt, Doctoral Graduate Student, Georgia Health Science University College of Graduate Studies – Thesis Committee Member (2008 – 2011)
5. Juhi Ojha, Doctoral Graduate Student, Georgia Health Science University College of Graduate Studies – Thesis Committee Member (2008 – 2011)
6. Ravi Padia, Doctoral Graduate Student, Georgia Regents University Graduate School – Thesis Committee Member (2008 – 2014)
7. Rui Wang, Doctorate Graduate Student, Georgia Regents University Graduate School – Thesis Committee Member (2009 – 2013)
8. Jae Kim, Doctorate Graduate Student, Georgia Health Science University College of Graduate Studies – Thesis Committee Member (2009 – 2011)
9. Roshini Prakash, Doctorate Graduate Student, University of Georgia School of Pharmacy – Thesis Committee Member (2009 – 2012)
10. Cristy Yu Qin, Doctoral Graduate Student, Georgia Health Science University College of Graduate Studies – Thesis Committee Member (2009 – 2011)
11. Kankana Bardhan, Doctoral Graduate Student, Georgia Regents University Graduate School – Thesis Committee Member (2009 – 2013)
12. Christina Torres, Doctoral Graduate Student, Georgia Regents University Graduate School – Thesis Committee Member (2012 – present)

13. Prasanna Abeyrathna, Doctoral Graduate Student, Georgia Regents University Graduate School – Thesis Committee Member (2012 – present)
14. Satish Kumar Noonepalle, Doctoral Graduate Student, Georgia Regents University Graduate School – Thesis Committee Member (2012 – present)

TRAINING EXPERIENCE

Current Lab Members:

Hina Rehmani, Ph.D. Graduate Student, Georgia Regents University Graduate School (7/2013 – present)

Dongdong Fang, (Ph.D., China Pharmaceutical University), Postdoctoral Fellow (12/2013 – present)

Wei Wang (B.S., Shanghai University of Traditional Chinese Medicine), Student Trainee (8/2014 – present)

Jessica Zhu (M.D., Tianjin Medical University), Postdoctoral Fellow (10/2014 – present)

Former Lab Members:

Qiwei Han (M.B.), Research Assistant (4/2000 – 7/2003). Currently, Medical Technologist, University of Mississippi School of Medicine, Jackson, MS

Jian Chen (M.D.), Postdoctoral Research Associate (12/2000 – 2/2002)

Dafang Tom Bian (Ph.D., Zhejiang University, China), Postdoctoral Research Associate (6/2001 – 5/2005)

Chitladda Mahanivong (Ph.D., University of Melbourne, Australia), Postdoctoral Research Associate (5/2002 – 12/2006)

Shibing Su (M.D., Ph.D.), Postdoctoral Research Associate (9/2004 – 10/2006). Currently, Professor and Director, Research Center for Traditional Chinese Medicine Complexity System, Shanghai University of Traditional Chinese Medicine, China

Jianqiang Yu (Ph.D., Fudan University, China), Postdoctoral Research Associate (7/2003 – 12/2006)

Hongbin Li (Ph.D.), Postdoctoral Research Associate (4/2004 – 7/2006)

Sook-Wah Yee (Ph.D.), Postdoctoral Research Associate (12/2005 – 2/2007). Currently, Academic Coordinator, University of California San Francisco

Haomin Chen (Ph.D., Tsinghua University, China), Postdoctoral Fellow (5/2007 – 8/2009). Currently, Professor, School of Life Science, Fudan University, Shanghai, China

Genfeng Zhu (B.S.), Research Technician (9/2008 – 8/2009). Currently, Scientist, School of Life Science, Fudan University, Shanghai, China

Nikki Harval (M.S., Southwestern Missouri State University), Research technician (7/2007 – 9/2009)

Huijun Chen, Doctoral Student from Medical College of Georgia/Wuhan University joining program (9/2007 – 10/2010). Currently, Attending Physician, Department of Obstetrics & Gynecology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China

Qinwei Hu (Ph.D., Peking Union Medical College, China), Postdoctoral Fellow (7/2008 – 4/2012)

Yong Li (Ph.D., University of Karlsruhe, Germany), Postdoctoral Fellow (10/2008 – 5/2012). Currently, Professor, Anhui University, Hefei, Anhui, China

Hyongsoon Noh, Doctoral Student in Georgia Regents University Graduate School (11/2007 – 5/2013). Currently, Postdoctoral fellow, University of Texas M.D. Anderson Cancer Center, Houston, TX

Jin Shao (B.S., Xiamen University, China), Student Trainee (2/2010 – 7/2013)

Hui Zhang (M.D., Ph.D., Shanghai University of Traditional Chinese Medicine), Visiting Scientist (12/2012 – 12/2013). Currently, Associate Professor, Shanghai University of Traditional Chinese Medicine

Sungguan Hong (Ph.D., University of Georgia), Postdoctoral fellow (8/2008 – 5/2014). Currently, Lecturer, University of Texas Health Science Center at Houston